STOCK TITAN
  1. Home
  2. News
  3. ABBV

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

News
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
Rhea-AI Summary
AbbVie (ABBV) launches PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease. The subcutaneous 24-hour infusion of levodopa-based therapy demonstrated sustained improvements in 'Off' time, 'On' time without dyskinesia, and morning akinesia. Parkinson's disease affects approximately 6.1 million people globally and is expected to double by 2040. PRODUODOPA provides continuous delivery of levodopa, extending the period when symptoms are well-controlled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Rhea-AI Summary
AbbVie (ABBV) announces Phase 2 results for lutikizumab in adults with hidradenitis suppurativa, showing higher response rates in HS Clinical Response (HiSCR 50) at week 16 than those treated with placebo. The study also revealed higher response rates in skin pain NRS30 at week 16 among patients with baseline NRS≥3. The program reflects AbbVie's leadership in immunology and a history of investigating new options for patients with HS, addressing a significant unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
clinical trial
-
News
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
Rhea-AI Summary
AbbVie (NYSE: ABBV) and Umoja Biopharma announced two exclusive option and license agreements to develop in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVecTM platform. The collaboration combines AbbVie's expertise in oncology with Umoja's gene delivery platform to advance next-generation in-situ CAR-T therapies. Umoja received upfront payments and an equity investment from AbbVie, with the potential to earn up to $1.44B in aggregate for option exercise fees, development and regulatory milestones, and additional sales-based milestones and tiered royalties on worldwide net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
News
AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
Rhea-AI Summary
AbbVie (NYSE: ABBV) to announce full-year and fourth-quarter 2023 financial results on February 2, 2024, before market opens. Live webcast of earnings conference call at 8 a.m. CT accessible through AbbVie's Investor Relations website at investors.abbvie.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences earnings
-
News
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
AbbVie (NYSE: ABBV) to participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Key executives to present at the event, with a live audio webcast accessible through AbbVie's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
News
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Rhea-AI Summary
Genmab A/S (GMAB) and AbbVie (ABBV) reported new data from the phase 1/2 EPCORE™ NHL-1 clinical trial for epcoritamab, showing an 82% overall response rate, 63% complete response rate, and 67% minimal residual disease negativity in patients with relapsed/refractory follicular lymphoma. The study presented at the 65th ASH Annual Meeting and Exposition also highlighted an optimized dosing schedule for FL patients, reducing the risk and severity of cytokine release syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Rhea-AI Summary
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates. The median duration of response was not reached. The FDA granted Breakthrough Therapy Designation to epcoritamab for the treatment of adult patients with R/R FL after two or more therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire Cerevel Therapeutics (NASDAQ: CERE) for a total equity value of approximately $8.7 billion. The acquisition adds a robust neuroscience pipeline to AbbVie's portfolio, focusing on psychiatric and neurological disorders. The transaction is expected to close in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
acquisition
-
News
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences collaborate to develop next-generation therapeutic antibodies in oncology and neuroscience. BigHat will receive $30 million upfront payment with potential for further milestone payments and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
News
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire ImmunoGen, Inc. (NASDAQ: IMGN) for $10.1 billion, accelerating its entry into the commercial market for ovarian cancer with the first-in-class antibody-drug conjugate (ADC) ELAHERE®. The transaction, valued at $31.26 per share, aims to diversify AbbVie's oncology pipeline across solid tumors and hematologic malignancies, with potential transformative impact on long-term revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
acquisition
Stock ABBV logo
Abbvie Inc

NYSE:ABBV

ABBV Rankings

#30 Ranked by Market Cap
#2312 Ranked by Stock Gains
#922 Ranked by Dividends

ABBV Stock Data

287.80B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.